Cargando…
Hemoglobin-Based Blood Substitutes and the Treatment of Sickle Cell Disease: More Harm than Help?
Intense efforts have been made by both industry and academia over the last three decades to produce viable hemoglobin (Hb)-based oxygen carriers (HBOCs), also known as “blood substitutes”. Human trials conducted so far by several manufactures in a variety of clinical indications, including trauma, a...
Autor principal: | Alayash, Abdu I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372714/ https://www.ncbi.nlm.nih.gov/pubmed/28054978 http://dx.doi.org/10.3390/biom7010002 |
Ejemplares similares
-
Effects of α subunit substitutions on the oxidation of βCys93 and the stability of sickle cell hemoglobin
por: Hicks, Wayne, et al.
Publicado: (2020) -
Substitutions in the β subunits of sickle-cell hemoglobin improve oxidative stability and increase the delay time of sickle-cell fiber formation
por: Meng, Fantao, et al.
Publicado: (2019) -
Hemoglobin Oxidation Reactions in Stored Blood
por: Alayash, Abdu I.
Publicado: (2022) -
Mechanisms of Toxicity and Modulation of Hemoglobin-based Oxygen Carriers
por: Alayash, Abdu I.
Publicado: (2019) -
Antisickling Drugs Targeting βCys93 Reduce Iron Oxidation and Oxidative Changes in Sickle Cell Hemoglobin
por: Kassa, Tigist, et al.
Publicado: (2019)